Open an account

Incyte

INCY · NASDAQ

$116.62+$3.37 (+2.97%)TodayMarket closed ·
Prev close $113.25

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Employees
2,844
Headquarters
Wilmington, Delaware
Listed
Dec 6, 1993
Sector
Health Care
Industry
Biotechnology
Website
incyte.com

INCY key statistics

Market cap
23.64B
Price-earnings ratio
14.43
Dividend yield
—
Average volume
1.72M
Volume
1.34M
Open price
$113.95
High today
$117.00
Low today
$113.26
52 Week high
$132.60
52 Week low
$84.02

Incyte (INCY) at a glance

Incyte (INCY) last traded at $116.62, with a market cap of 23.64B and a price-to-earnings ratio of 14.43.

Today the stock has traded between $113.26 and $117.00. The current price is 3.0% above the day's low and 0.3% below its high.

Volume so far is 1.34M shares, below the average of 1.72M shares a day.

Over the past year Incyte has ranged from $84.02 to $132.60, and now sits 67% of the way up that range.

Incyte met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $3.09 per share against an estimate of $2.14.

The average analyst price target is $130.68, 12.1% above the current price, from 23 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

48%of 23 analyst ratings say Buy
  • Buy47.8%
  • Hold52.2%
  • Sell0.0%
Price target · 27 analystsAvg $130.68
Low
$88.60
Now
$116.62
High
$162.75

INCY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 24.8% on average.

  1. Q3 FY24: reported $1.07 per share against an estimate of $1.09
  2. Q4 FY24: reported $1.43 per share against an estimate of $1.59
  3. Q1 FY25: reported $1.16 per share against an estimate of $1.04
  4. Q2 FY25: reported $1.57 per share against an estimate of $1.50
  5. Q3 FY25: reported $2.26 per share against an estimate of $1.69
  6. Q4 FY25: reported $1.80 per share against an estimate of $1.97
  7. Q1 FY26: reported $1.81 per share against an estimate of $1.40
  8. Q2 FY26: reported $3.09 per share against an estimate of $2.14

INCY news

  • Press releaseBusiness Wire

    Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

  • Vandana Singh

    Why Is Arcutis Biotherapeutics Stock Surging Thursday?

  • Press releaseBusiness Wire

    Incyte to Report Third Quarter Financial Results

  • Vandana Singh

    FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

  • Press releasePRNewswire

    MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

  • Vandana Singh

    Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

  • FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily

Similar companies

Companies in the same industry as Incyte

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.